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Abstract
Lungs are exposed to the outside environment and therefore to toxic and infectious agents or
allergens. This may lead to permanent activation of innate immune response elements. A
Disintegrin  And  Metalloproteinases (ADAMs) and ADAMs with Thrombospondin motifs
(ADAMTS) are proteinases closely related to Matrix Metalloproteinases (MMPs). These
multifaceted molecules bear metalloproteinase and disintegrin domains endowing them with
features of both proteinases and adhesion molecules. Proteinases of the ADAM family are
associated to various physiological and pathological processes and display a wide spectrum of
biological effects encompassing cell fusion, cell adhesion, "shedding process", cleavage of various
substrates from the extracellular matrix, growth factors or cytokines... This review will focus on
the putative roles of ADAM/ADAMTS proteinases in airway diseases such as asthma and COPD.
Introduction
The lung is continuously exposed to the outside environ-
ment and various potential aggressions such as noxious
and infectious agents or allergens. The innate immune
responses are permanently activated in this particular
organ. Moreover, secretory materials such as surfactant
and mucous also contribute to host defense against
inflammation. Among airway diseases, asthma and
COPD (Chronic Obstructive Pulmonary Disease) appear
to be growing public health concerns worldwide and the
number of listed asthmatic and COPD patients still
increases over time.
Asthma is a complex clinically-defined syndrome mainly
characterized by symptoms (wheezing, cough, breathless-
ness) and airway obstruction. Hallmarks of asthma are
mainly airway hyperresponsiveness caused by a wide vari-
ety of stimuli and airway inflammation involving eosi-
nophils and mast cells. Moreover, an asthma-associated
remodeling of the airways including extensive changes in
the extracellular matrix has been characterized. The main
changes reported are a subepithelial fibrosis, a smooth
muscle hypertrophy, a glandular metaplasia in the bron-
chial epithelium, and the deposition of extracellular
matrix components throughout the airway wall. These
features are very often associated with altered behaviour
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of airway structural cells including epithelial cells or
fibroblasts [1,2].
COPD is characterized by a progressive airway obstruction
mainly linked to tobacco consumption and/or toxic
fumes and other environmental factors. COPD patients
also display profound modifications of the extracellular
matrix leading to an airway remodeling including colla-
gen fibers deposition in the bronchial and bronchiolar
walls, mucous hyperplasia, and smooth muscle cell
hypertrophy [3-5].
As the key role of extracellular matrix and soluble media-
tors has been unveiled, there is accumulating evidences
demonstrating the crucial role played by matrix metallo-
proteinases (MMPs) in lung diseases [6,7]. These aspects
have been largely discussed in previous reviews [8,9]. The
present review focuses on another subfamily of protein-
ases also belonging to the metzincins (zinc-bearing pro-
teinases) and structurally related to MMPs: the ADAMs (A
Disintegrin And Metalloproteinase) [10-14]. ADAM pro-
teinases have been described as "signalling scissors" since
they are associated to shedding processes of key factors
implicated in physiological as well as in pathological
activities [15]. This shedding process is quite interesting as
it appears as an emerging concept that could be impli-
cated in airway diseases. Indeed, ADAM-17 has been
defined as the prototypical TNF-α convertase enzyme
[16]. Besides this very well known example, many other
sheddase activities have been reported and can address
many physiological processes such as the regulation of
cell proliferation by cleavage of membrane-bound
heparin-binding epidermal growth factor (HB-EGF) [17].
Some cell receptors including the low-affinity immu-
noglobulin E receptor (CD23) can also be targeted by
sheddases. Indeed, ADAM-10 appears to be the main
sheddase for CD23 leading to increased levels of its solu-
ble form [18,19]. The literature emerging in the last years
suggests that ADAMs scissors-function plays a crucial role
in airway diseases.
In the present review, after a brief general description of
ADAM proteins, we discuss the implications of these pro-
teinases in various physiological and pathological proc-
esses. The potential contribution of ADAM/ADAMTS
proteins to asthma pathology will be described as well as
ADAMs/ADAMTS' involvement in COPD.
Structural features of ADAMs
To date, about 40 members of the ADAM family have
been described in different species (for a constantly
updated database, see http://people.virginia.edu/~jw7g/
Table_of_the_ADAMs.html and http://degra
dome.uniovi.es/). Twenty-five ADAMs are expressed in
Homo sapiens while thirty-five members are expressed in
Mus musculus. Together with ADAMTS (ADAMs with
Thrombospondin motifs type I) and SVMPs (Snake
Venom  Metalloproteinases), ADAM proteinases consti-
tute the subfamily of adamalysins [12] which belongs to
the superfamily of metzincins. This superfamily also
includes astacins, matrixins (also referred to as matrix
metalloproteinases), serralysins and pappalysins [20,21].
Those metzincins are characterized by (1) a catalytic site
containing a consensus sequence (HEXXHXXGXXH) in
which three histidine residues coordinate a zinc ion and
(2) by a conserved methionine residue forming a "Met-
turn" beneath the active zinc site. This "Met-turn" pro-
vides a hydrophobic environment for the zinc ion and the
three ligating histidine residues at the catalytic centre of
the enzyme [22,23].
Structure of ADAMs and ADAMTS is highly conserved and
involves metalloproteinase and disintegrin domains
endowing them with features of both proteinases and
adhesion molecules [11,13]. As illustrated in figure 1, the
detailed structure of ADAMs is far more complex than that
of MMPs. Domains shared with MMPs are the prodomain
maintaining the catalytic site inactive and the metallopro-
teinase domain containing the Zinc binding site. ADAM
activation mechanisms are mostly similar to MMP's acti-
vation and generally imply the prodomain removal from
the precursor protein via a proprotein convertase of furin
type [24]. However, maturation of some ADAMs, such as
ADAM-8 and ADAM-28 occurs as an autocatalytic process
[25,26]. The metalloproteinase domain with its catalytic
consensus site is active in only about half of ADAM pro-
teinases. The following domains are characteristic of
ADAMs and include a disintegrin domain mediating cell-
cell, cell-matrix interactions via the interaction with
integrins; a cystein-rich domain implicated in cell adhe-
sion; an epidermal growth factor (EGF)-like domain and
a cytoplasmic tail involved in various intracellular signal-
ization pathways [11].
Although the structure of ADAM and ADAMTS protein-
ases is closely related, ADAMTS molecules are character-
ized by a various number of thrombospondin type one
motifs (TSP-1) at their C-terminal end and the absence of
transmembrane and cytoplasmic domains [10,27] (figure
1). In the C-terminal extremity, different types of modules
have been described for some of the ADAMTS. All these
data are regularly updated on http://www.lerner.ccf.org/
bme/apte/adamts.
The metalloproteinase system is controlled by endog-
enous physiological inhibitors ("Tissue Inhibitors of Met-
alloproteinases" or TIMPs) which are small proteins with
molecular weights ranging from 21 to 28 kDa. These
inhibitors display six disulfide bonds in their structure
forming a rigid conformation which is mandatory forRespiratory Research 2009, 10:127 http://respiratory-research.com/content/10/1/127
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their biological activity. TIMPs are able to inhibit protein-
ase activity of several members of the ADAM family [28-
31]. N-terminal domain of TIMPs and more specifically
the "functional binding edge" is interacting with the cata-
lytic domain of the ADAM proteinase [32]. The interac-
tion of the catalytic site-bound Zinc atom with a cystein
present in the N-terminal extremity of TIMP leads to an
inactivation of ADAMs. This process has been described
for ADAM-17 or ADAMTS-4 interacting with TIMP-3
[30,32]. More recently, a novel method of purification
using sodium chlorate has confirmed that C-terminal
domain of ADAMTS-4 and -5 and more particularly their
TS-domains favors the interaction with the N-terminal
domain of TIMP-3 [33].
When taking into consideration the complex multi-
domain structure of ADAMs and ADAMTS, one can antic-
ipate their implication in many physiological and patho-
logical processes. From these complex structural features
and bearing in mind that only half of proteins of this fam-
ily display a catalytic activity, one can expect that func-
tions of ADAMs and ADAMTS will not be restricted to the
Structural organization of MMPs, ADAMs and ADAMTS Figure 1
Structural organization of MMPs, ADAMs and ADAMTS. The typical structure of MMP is made of a prodomain, a furin 
cleavage site (all MT-MMPs, MMP-21,-23, and -28), a catalytic metalloproteinase domain with fibronectin type II repeats (MMP-
2, MMP-9), a linker peptide and a haemopexin domain (except for MMP-7, -26, and -23), a linker peptide, a transmembrane 
domain and cytoplasmic tail (MMP-14, -15, -16, -24) or glycosylphosphatidylinositol (GPI) anchor (MMP-17, -25). MMP-23 bears 
C-terminal cysteine-rich (Cys-rich) and Ig-like (Ig) domains and its propeptide lacks a cystein switch motif. Common structure 
of ADAMs is a prodomain, a cleavage site (by a furin or furin-like proprotein convertase except for ADAM-8 and ADAM-28 
which use an autocatalytic process), a metalloproteinase domain, a disintegrin domain, a cysteine-rich region (Cys-rich), an epi-
dermal-growth factor repeat (EGF-like), a transmembrane domain (TM) and a cytoplasmic tail. ADAMTS do not possess a 
transmembrane domain (TM) but bear a various number of thrombospondin type I motifs (TSP-1) at their C-terminal extrem-
ity.Respiratory Research 2009, 10:127 http://respiratory-research.com/content/10/1/127
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cleavage of extracellular matrix or mediators but will
embrace various functions including the regulation of
cell-cell and cell-matrix interactions. Although these
ADAM/ADAMTS functions are not yet as much discerned
as those of MMPs, a real interest from the scientific com-
munity has emerged these last years, specifying not only
the exact structure of these proteins, but also identifying
new features involving ADAMs in health and diseases. In
this review, we are discussing known and potential impli-
cations of ADAMs in lung homeostasis as well as in its
deregulation.
Implication of ADAMs and ADAMTS in 
physiological and pathological processes
Since ADAM proteinases are defined as multi-domain
proteins, studies have focused their attention on the mul-
tiple functions that can be ascribed to these proteinases.
ADAMs have been described in various physiological
processes such as egg fertilization, myogenesis, cell fate
determination but also in diverse pathological processes.
Physiological processes
Properties attributed to ADAMs are evidently crucial when
one considers their structural organization. We will
present hereafter selected examples illustrating the diver-
sity of biological processes that can be affected by ADAM
proteins. Most of ADAMs are membrane-bound proteins
and can assist cell fusion, cell adhesion, peptidic media-
tors processing, linked or not to plasma membrane. They
also play a key role in some intracellular signaling path-
ways. The final picture is rendered even more complex
since alternative splicing can induce variations in the C-
terminal region of membrane-bound ADAMs and thereby
give rise to different cytosolic tails or secreted proteins
[34].
Some ADAMs appear essential in cell fusion processes. It
is worth underlining that the two first identified ADAMs
(ADAM-1 and -2) were recognized as fertilin-alpha and -
beta in 1987 [35] since they could induce the fusion of the
sperm with the egg. This process is mediated through the
interaction of the disintegrin domain of ADAM-2 present
on the sperm with integrin α6β1 beared on the egg surface
[36]. Moreover, ADAM proteins are key enzymes in
embryonic development since ADAM-10 is able to cleave
NOTCH protein and consequently regulate central nerv-
ous system development [37]. ADAMs also contribute to
intracellular signalling processes and have the ability to
interact with tyrosine kinases and some components of
the cytoskeleton through their cytoplasmic domain [11].
The disintegrin domain of some ADAMs is able to regulate
cell adhesion through interaction with various integrins.
For instance ADAM-15 is described as a novel component
of adherens junctions [38]. Importantly, as stated earlier,
ADAMs/ADAMTS are able to cleave membrane-bound
growth factors, cytokines and proteoglycans, leading to
the detachment of mature soluble forms. This process is
largely referred to as sheddase activity. So far, the most
studied sheddases are ADAM-17 and ADAM-10 responsi-
ble for the cleavage of pro-TNF and CD23, respectively
[16,18,39]. ADAMTS proteinases also display a catalytic
activity. Indeed, ADAMTS-4 and ADAMTS-5 are able to
cleave aggrecan [40,41], ADAMTS-2 processes type I, II
and III procollagen chains [42].
Pathological processes
Dysregulation of ADAMs expression has been reported in
different types of pathologies such as cancer, osteoarthri-
tis, neurodegenerative inflammation or asthma. In most
studies, an overexpression of these proteinases has been
described and is linked to a dysregulation of tissue home-
ostasis sometimes leading to a specific pathological phe-
notype. ADAMs might therefore be considered as
potential candidates to target in a therapeutic setting. For
instance, ADAM-17 expression is increased in breast can-
cer tissues and its expression is higher in advanced-grade
than low-grade tumors. Patients displaying a huge expres-
sion of this proteinase have a shorter overall survival than
those with a low expression of ADAM-17 [43] suggesting
that ADAM-17 might be a good target to predict the out-
come of cancer development. ADAMTS-4 and ADAMTS-5
are implicated in osteoarthritis development since
ADAMTS-4/-5 double-knockout animals are less affected
than wild-type mice [44,45]. Alzheimer's disease is char-
acterized by beta amyloid deposition in the brain. ADAM-
10 acts as an alpha-secretase and thereby cleaves the amy-
loid precursor to release a soluble component. Many
authors have hypothesized that overexpression of ADAM-
10 might have beneficial effects on the pathological dep-
osition of amyloid protein [46,47] since ADAM-10 over-
expressing mice display reduced susceptibility to amyloid
deposition [47].
The complex structure of ADAMs also suggests that these
enzymes may be functionally relevant to different steps
linked to asthma pathogenesis. Indeed, the active metallo-
proteinase domain of some ADAMs might be important
to shed growth factors and cytokines, contributing in this
way to the control of inflammation which is a hallmark of
asthma pathology. Disintegrin domain might also act in
concert with cystein-rich region to interfere with pro-
inflammatory cytokines [48].
These data illustrate how much ADAMs are multifunc-
tional proteins and suggest that these proteinases may
serve as mediators during the progression of asthmatic
pathology but also COPD (table 1).
Expression of ADAMs and ADAMTS in the lung
In the lung, different cell types can express different classes
of proteinases. Some structural cells from bronchial tree
are able to produce enzymes belonging to the metzincinRespiratory Research 2009, 10:127 http://respiratory-research.com/content/10/1/127
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superfamily that are important in regulation processes
and in the cascade leading to inflammation. However,
some data - especially those concerning the expression of
ADAMs in lung tissues - are more recent and rather incom-
plete [49] (table 2). In lung tissue, an expression of
ADAM-8, -9, -10, -12, -15, -17 and ADAMTS-1, -2, and TS-
12 has been observed [50] with a modulation of ADAM-
12 and ADAMTS-1 in tumors [50]. In sputum cells, an
expression of ADAM-8, -9, -10, -12, -15, -17 and
ADAMTS-1, TS-15 has been reported [51]. Moreover, epi-
thelial cells have been shown to express ADAM-9, -10, -
12, -15, -17 and ADAMTS-1 with an exception for immor-
talized bronchial epithelial cells (BEAS-2B) which do not
express ADAM-12 [50]. Another epithelial cell line (A549,
an alveolar epithelial cell line) was shown to express
ADAM-19 and ADAMTS-9 [52]. Whereas mesenchymal
cells such as fibroblasts and smooth muscle cells abun-
dantly express ADAM-33 [53-55], epithelial cells may also
express this proteinase [49,56]. Although only some
authors have reported that airway epithelial cells express
ADAM-8 [57,58], all authors have agreed to confirm that
inflammatory cells produce ADAM-8, a proteinase that
has been suggested to be a key mediator in inflammatory
processes [51,57-60].
Contribution of ADAM and ADAMTS 
proteinases to the asthmatic phenotype
In some individuals, an inflammatory reaction occurs in
the lungs after exposure to specific allergens. Following a
single allergen exposure, an early-phase reaction is pro-
duced in pulmonary tissues followed by a late-phase reac-
tion. The early-phase reaction is characterized by the
activation of mast cells and macrophages and the release
of various mediators including histamine and eicosanoids
while the late-phase reaction consists of recruitment of
eosinophils, CD4+  T cells, basophils and neutrophils.
Moreover, T helper cells amplify the inflammatory
response via the release of Th2 cytokines. Following repet-
itive exposure to allergens, a chronic inflammation devel-
ops with associated tissue alterations such as mucus
hypersecretion, vascular leakage, smooth muscle contrac-
tion, and bronchial hyperresponsiveness [61]. Asthma is
associated to an airway remodeling that includes 1) a sub-
epithelial fibrosis which appears as a pathognomonic fea-
ture of asthmatic bronchi, 2) changes in extracellular
matrix composition with an absence of classical compo-
nents of basement membrane (mainly collagen IV and
laminin) and a fragmentation of elastic fibers, 3) a goblet
cells hyperplasia and 4) increased angiogenesis [62].
Table 1: ADAMs/ADAMTS modulation in airway diseases.
ADAMs Modulation Type of airway disease Type of study Reference
ADAM-8 â asthma human [51,57,74]
â asthma mouse [58-60,73][Paulissen et al, submitted]
ADAM-9 â asthma human [51]
ADAM-10 â asthma mouse [73]
ADAM-12 â asthma human [51]
ADAM-17 â asthma mouse [73]
â COPD rat [80]
ADAM-28 â asthma mouse [73]
ADAM33 â asthma human [57,71,82]
SNP COPD human [79,83]
ADAMTS-1 ä asthma human [51]
ADAMTS-12 SNP asthma human [84]
ADAMTS-15 ä asthma human [51]
â asthma mouse [73]
SNP: Single Nucleotide PolymorphismRespiratory Research 2009, 10:127 http://respiratory-research.com/content/10/1/127
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Over the last years, the attention has risen about the roles
of ADAM proteinases in processes leading to the asth-
matic phenotype described above (see figure 2). ADAM-
33 was one of the first ADAM proteinases to be identified
as an asthma susceptibility gene after an ambitious study
based on a vast genome screening [53]. An association of
ADAM-33 gene polymorphism with the hyperresponsive-
ness linked to the asthmatic pathology has now been con-
firmed by many studies [63-66]. However, these data need
to be clarified since not all authors report such a link
between asthma and ADAM-33 [67,68]. These studies
linking asthma and variants in ADAM-33 gene are sum-
marized in table 3. Discrepancies between published stud-
ies can be explained by the diversity of studied
populations and the complexity of this gene subject to
alternative splicing processes. Moreover, important differ-
ences of statistical power of all these studies might also
account for some of the reported differences between
cohorts. Molecular mechanisms and exact roles of ADAM-
33 in the pathological process leading to asthma are there-
fore not yet fully elucidated. While it was reported that
ADAM-33 expression is mainly detectable in smooth
muscle cells and in fibroblasts, authors have recently
shown that ADAM-33 is also expressed by other cell types
including endothelial cells [49,69]. ADAM-33 therefore
might play a key role in asthma-associated airway remod-
eling since the purified catalytic domain of this proteinase
provokes an increased development of the vascular net-
work in asthmatic patients [70]. An argument to speculate
for a possible key role of ADAM-33 in asthma physiopa-
thology is the increased ADAM-33 expression reported
after stimulation by some Th2 cytokines (IL-4 and IL-13)
[71]. In humans, the expression of ADAM-33 was
reported to be correlated to disease severity. Indeed,
severe asthmatics display higher levels of ADAM-33
expression in their bronchial biopsies when compared to
mild asthmatics or controls. Moreover, these asthmatics
exhibit ADAM-33 staining in epithelial, submucosal and
smooth muscle cells as demonstrated by immunohisto-
chemistry [57]. This overexpression of ADAM-33 in the
airways of asthmatics was also confirmed in animal mod-
els. Indeed, ADAM-33 levels were reported to increase in
lungs of mice after allergen exposure [71]. Nevertheless,
the demonstration of ADAM-33 implication in patholog-
ical processes leading to an asthma phenotype is still not
fully accomplished. Indeed, phenotypes obtained in
Table 2: ADAMs/ADAMTS expression in lung cell types.
ADAMs Lung cell types Reference
ADAM-8 epithelial cells [49,57,58]
inflammatory cells [51,57,59][Paulissen et al, submitted]
smooth muscle cells [57](-) [58](+)
ADAM-9 epithelial cells [49,85]
inflammatory cells [49]
smooth muscle cells [49]
ADAM-10 epithelial cells [49]
smooth muscle cells [49]
ADAM-12 inflammatory cells [50]
smooth muscle cells [50]
ADAM-17 epithelial cells [49,86]
inflammatory cells [49]
smooth muscle cells [49]
ADAM-19 epithelial cells [49,52]
endothelial cells [49]
inflammatory cells [49]
smooth muscle cells [49]
ADAM-28 epithelial cells [87]
ADAM-33 epithelial cells [57](+) [88](-)
endothelial cells [49]
fibroblasts [54,88]
inflammatory cells [49,57]
smooth muscle cells [55,57,82,88]Respiratory Research 2009, 10:127 http://respiratory-research.com/content/10/1/127
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ADAM-33 KO mice did not suggest that the absence of
ADAM-33 actually modulates baseline or allergen-
induced airway responsiveness [72].
ADAM-8 is another member of the ADAM family poten-
tially associated to asthma. The first report to suggest an
ADAM-8 implication in asthma was published in 2004
[59]. This microarray study has shown that ADAM-8
expression is increased in mice exposed to allergens [59].
In 2008, another microarray study has confirmed the
involvement of ADAM-8 in an acute model of asthma,
mimicking the inflammation found in human airways,
while no difference was found in the chronic model of
asthma mimicking human airway remodeling [73]. More-
over, ADAM-8 mRNA levels are increased in sputum cells
from asthmatic patients when compared to healthy sub-
jects [51]. An immunohistochemistry targeting ADAM-8
has shown an elevated production of this proteinase in
bronchial biopsies from asthmatics related to disease
severity as reported for ADAM-33 [57]. A genomic study
has recently reported a link between ADAM-8 single
nucleotide polymorphisms and asthma in humans [74].
As membrane-bound CD23 is processed by ADAM-8 lead-
ing to ectodomain cleavage and resulting in the release of
a soluble form of CD23 (sCD23), the low-affinity IgE
receptor, ADAM-8 could take part to the cascade of events
leading to asthma phenotype [51]. ADAM-8 has already
been described to be a sheddase for CD23 [18,75]. The
proteolytic release of CD23 from cells is likely to be a key
event in allergic asthma. ADAM-8 also cleaves important
Intervention of ADAM/ADAMTS proteinases in asthma and COPD Figure 2
Intervention of ADAM/ADAMTS proteinases in asthma and COPD. Succinctly, in asthma, inhaled allergens provoke 
the degranulation of sensitized mast cells and the activation of epithelial cells (EC) while in COPD, inhaled cigarette smoke acti-
vates epithelial cells and macrophages. After a first challenge in both diseases, an inflammatory reaction occurs resulting in the 
recruitment of eosinophils and CD4+ T cells for asthma, neutrophils and CD8+ T cells for COPD. Following a chronic inflam-
mation, tissue alterations such as mucus hypersecretion, bronchoconstriction appear in asthma while small airway fibrosis, 
alveolar destruction (emphysema) and mucus hypersecretion occur in COPD. An airway hyperresponsiveness is linked to both 
diseases. However, it is reversible in asthma but not in COPD. ADAM-8 plays a role in asthma-related inflammation while 
ADAM-33 is associated to remodeling processes and hyperresponsiveness associated to asthma. In COPD, ADAM-17 acts on 
mucus hypersecretion process while ADAM-33 is associated with COPD-related hyperresponsiveness.Respiratory Research 2009, 10:127 http://respiratory-research.com/content/10/1/127
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effectors in asthma pathology such as pro-TNF-α and L-
selectin [75,76]. Moreover, ADAM-8 is involved in macro-
phages activation [75]. The pharmacological delivery of
IL-4 or IL-13 as well as use of mice transgene overexpress-
ing these interleukins enhance ADAM-8 levels when mice
are exposed to allergens suggesting that ADAM-8 depends
not only from allergens but also from Th2 cytokines [59].
Other authors have studied the effects of an overexpres-
sion of a soluble form of ADAM-8 by liver tissue and did
not find any difference regarding asthma phenotype [60].
Recently, we demonstrated that ADAM-8 is overexpressed
in lungs from mice experimentally exposed to allergens
and that the depletion of ADAM-8 by the use of KO ani-
mals or by immunodepletion dramatically decrease air-
way inflammation after allergen exposure (Paulissen et al,
submitted). It is also worth noting that these ADAM-8
depleted animals do not display developmental abnor-
malities as described by Kelly et al [77]. Taken together,
these data strongly suggest that ADAM-8 is a key mediator
in asthma. Further studies should be performed in order
Table 3: ADAM-33 polymorphism studies in human populations.
Type of study Population Linkage asthma Studied polymorphisms Reference
FBAS; CC; LDT UK Caucasian yes 135 [53]
US Caucasian
FBAS; CC Hispanic no 6 [68]
CC African from US yes 8 [65]
White from US
Hispanic from US
Dutch white
FBAS; CC German yes 15 [64]
CC Korean yes 5 [89]
FBAS North American * no 17 [90]
LDT Dutch Caucasian yes 8 [91]
LDT UK yes 17 [92]
CC German white * no 10 [93]
CC Japanese yes 14 [66]
FBAS Japenese * yes 23 [63]
CC Australian Caucasian yes 10 [94]
CC Northeast Chinese no 3 [67]
FBAS European-American * no ND [95]
hispanic * no ND [95]
allele frequency Japenese yes 10 [96]
CC Northeast Chinese yes 6 [97]
allele frequency Thai yes 8 [98]
CC Northeast Chinese yes 6 [99]
FBAS; CC UK yes 4 [100]
Family- based association study: FBAS; Case-control study: CC; linkage disequilibrium test: LDT; ND: no determined; *: childrenRespiratory Research 2009, 10:127 http://respiratory-research.com/content/10/1/127
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to unveil the exact mechanisms implicating ADAM-8 in
this disease.
Besides ADAM-8 overexpression, a modulation of RNA
levels of ADAM-9, ADAM-12, ADAMTS-1 and ADAMTS-
15 has been demonstrated in induced sputum from asth-
matic patients [51]. Recently, a genomic study has dem-
onstrated that many ADAM and ADAMTS proteinases
such as ADAM-10,-17,-28 and ADAMTS-4, -9,-15 are also
overexpressed in chronic asthma [73]. However, further
studies might be led to explore their potential role in
asthma-related pathology.
All these data highlight the implication of ADAM protein-
ases in asthma pathogenesis and suggest that new thera-
peutic strategies based on the inhibition of certain
members of this proteinases family could be investigated.
Contribution of ADAM and ADAMTS 
proteinases in COPD
Chronic obstructive pulmonary disease (COPD) is char-
acterized by a destruction of the lung parenchyma leading
to alveolar wall destruction (emphysema) and important
structural alterations in bronchial walls such as epithelial
metaplasia or airway wall fibrosis [4]. The major risk fac-
tor for COPD is the inhalation of cigarette smoke. Despite
the improvement of therapeutic strategies and a better
understanding of this disease, the morbidity and mortal-
ity related to COPD are still significant. Matrix metallo-
proteinases such as MMP-9 and MMP-12 which have been
reported to be modulated in airway secretions from
COPD patients might contribute to disease progression
and exacerbations by their catalytic activity. However,
despite their potential importance in this disease, only
few data are available concerning ADAM proteinases
involvement in COPD (see figure 2).
ADAM-33 has also been identified as a susceptibility gene
for COPD since single nucleotide polymorphisms (SNPs)
observed in this gene are associated with a higher risk for
developing COPD [78]. ADAM-33 has recently been
reported to be linked to airway hyperresponsiveness and
airway inflammation in the general population suffering
from COPD [79].
Data describing higher ADAM-17 (TACE for TNF-alpha
converting enzyme) production in lung tissues from rats
exposed to tobacco in a COPD model as compared to con-
trol animals support the implication of ADAM protein-
ases in this obstructive lung pathology [80]. Moreover,
siRNA (small interfering RNA) raised against ADAM-17
mRNA as well as metalloproteinase inhibitors (GM-6001
and TNF-alpha inhibitor 1), prevent smoking- induced
mucin overproduction in human airway epithelial cells
(NCI-H292 cells) [81].
Conclusions
Many peptidic mediators secreted in the lung by both
structural as well as inflammatory cells are implicated in
physiological processes and their overexpression or inhi-
bition is in many cases part of intrinsic pathological
mechanisms. ADAMs and ADAMTS proteins can cleave
many of these factors and are therefore key mediators for
the control of many biological processes in the lung.
Among other activities, these proteinases are also active in
the control of extracellular matrix homeostasis and cell
migration. It seems therefore logical to set up some thera-
peutic strategies to target ADAM(TS) enzymes activity in
obstructive airways diseases.
This review, aiming at summarizing some lung-related
biological actions of ADAMs/ADAMTS, demonstrates to
which extent these factors are important in both physio-
logical and pathological processes in lung tissues. Many
basic researches have still to be performed to clearly iden-
tify target proteinases that appear to play a direct role in
pathogenesis as well as potential anti-target ADAMs whose
inhibition could cause damages because they have a direct
or indirect beneficial effect on lung physiology.
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